These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24464577)

  • 1. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.
    Lim RC; Price JT; Wilce JA
    Breast Cancer Res Treat; 2014 Feb; 143(3):593-603. PubMed ID: 24464577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRB7 is required for triple-negative breast cancer cell invasion and survival.
    Giricz O; Calvo V; Pero SC; Krag DN; Sparano JA; Kenny PA
    Breast Cancer Res Treat; 2012 Jun; 133(2):607-15. PubMed ID: 22005836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCF12-regulated GRB7 facilitates the HER2+ breast cancer progression by activating Notch1 signaling pathway.
    Wang G; Wu Y; Su Y; Qu N; Chen B; Zhou D; Yuan L; Yin M; Liu M; Zhou W
    J Transl Med; 2024 Aug; 22(1):745. PubMed ID: 39113057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
    Tang Y; Yang S; Wang M; Liu D; Liu Y; Zhang Y; Zhang Q
    Int J Mol Med; 2019 Jun; 43(6):2352-2360. PubMed ID: 31017268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity.
    Sang J; Kulkarni K; Watson GM; Ma X; Craik DJ; Henriques ST; Poth AG; Benfield AH; Wilce JA
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31627265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRB7 protein over-expression and clinical outcome in breast cancer.
    Ramsey B; Bai T; Hanlon Newell A; Troxell M; Park B; Olson S; Keenan E; Luoh SW
    Breast Cancer Res Treat; 2011 Jun; 127(3):659-69. PubMed ID: 20635137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma.
    Bivin WW; Yergiyev O; Bunker ML; Silverman JF; Krishnamurti U
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):553-558. PubMed ID: 26945445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
    Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
    Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines.
    Hevir N; Trošt N; Debeljak N; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):206-16. PubMed ID: 21182832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer.
    Glynn RW; Miller N; Mahon S; Kerin MJ
    Oncol Rep; 2012 Jul; 28(1):365-9. PubMed ID: 22552811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.
    Wang K; Xie S; Ren Y; Xia H; Zhang X; He J
    Oncol Rep; 2012 Jun; 27(6):1981-9. PubMed ID: 22446691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
    Sparano JA; Goldstein LJ; Childs BH; Shak S; Brassard D; Badve S; Baehner FL; Bugarini R; Rowley S; Perez EA; Shulman LN; Martino S; Davidson NE; Kenny PA; Sledge GW; Gray R
    Clin Cancer Res; 2011 Nov; 17(22):7194-203. PubMed ID: 21933890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.
    McCleland ML; Adler AS; Shang Y; Hunsaker T; Truong T; Peterson D; Torres E; Li L; Haley B; Stephan JP; Belvin M; Hatzivassiliou G; Blackwood EM; Corson L; Evangelista M; Zha J; Firestein R
    Cancer Res; 2012 Nov; 72(22):5812-23. PubMed ID: 23139210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.